2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Flushing: new trials by email Literature Review of Flushing trials Research Report on Flushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Lanreotide, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Ipsen | 115 | 2009-05-01 | 2022-10-14 |
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks - Flushing | Phase 3 | Completed | Merck Sharp & Dohme LLC | 330 | 2007-04-01 | 2017-02-17 |
Carcinoid Tumor (1) · Diarrhea (1) · Neuroendocrine Tumors (1) · Serotonin Syndrome (1)
Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Skin Manifestations (2) · Adenocarcinoma (1) · Carcinoma (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Signs and Symptoms, Digestive (1)
Duration of Therapy (1) · lanreotide (1)
Ipsen (1) · Merck Sharp & Dohme LLC (1)
Brazil (1) · Czechia (1) · India (1) · Latvia (1) · Poland (1) · Russia (1) · Serbia (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1) · United States (1)